These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 11536154)

  • 21. Immune interaction between respiratory syncytial virus infection and allergen sensitization critically depends on timing of challenges.
    Peebles RS; Hashimoto K; Collins RD; Jarzecka K; Furlong J; Mitchell DB; Sheller JR; Graham BS
    J Infect Dis; 2001 Dec; 184(11):1374-9. PubMed ID: 11709778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease.
    Lee YN; Hwang HS; Kim MC; Lee YT; Lee JS; Moore ML; Kang SM
    Antiviral Res; 2015 Mar; 115():1-8. PubMed ID: 25513755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential mechanisms causing delayed effects of respiratory syncytial virus infection.
    Openshaw PJ
    Am J Respir Crit Care Med; 2001 Mar; 163(3 Pt 2):S10-3. PubMed ID: 11254545
    [No Abstract]   [Full Text] [Related]  

  • 24. The role of IFN in respiratory syncytial virus pathogenesis.
    Durbin JE; Johnson TR; Durbin RK; Mertz SE; Morotti RA; Peebles RS; Graham BS
    J Immunol; 2002 Mar; 168(6):2944-52. PubMed ID: 11884466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peripheral blood cytokine responses and disease severity in respiratory syncytial virus bronchiolitis.
    Bont L; Heijnen CJ; Kavelaars A; van Aalderen WM; Brus F; Draaisma JT; Geelen SM; van Vught HJ; Kimpen JL
    Eur Respir J; 1999 Jul; 14(1):144-9. PubMed ID: 10489842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased innate immune cytokine responses correlate with disease severity in children with respiratory syncytial virus and human rhinovirus bronchiolitis.
    García C; Soriano-Fallas A; Lozano J; Leos N; Gomez AM; Ramilo O; Mejias A
    Pediatr Infect Dis J; 2012 Jan; 31(1):86-9. PubMed ID: 21829141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LAIR-1 limits neutrophil extracellular trap formation in viral bronchiolitis.
    Geerdink RJ; Hennus MP; Westerlaken GHA; Abrahams AC; Albers KI; Walk J; Wesselink E; Janssen R; Bont L; Meyaard L
    J Allergy Clin Immunol; 2018 Feb; 141(2):811-814. PubMed ID: 29050972
    [No Abstract]   [Full Text] [Related]  

  • 28. CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse.
    Tripp RA; Jones L; Anderson LJ; Brown MP
    J Immunol; 2000 Jun; 164(11):5913-21. PubMed ID: 10820273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional disorder of primary immunity responding to respiratory syncytial virus infection in offspring mice exposed to a flame retardant, decabrominated diphenyl ether, perinatally.
    Watanabe W; Shimizu T; Sawamura R; Hino A; Konno K; Kurokawa M
    J Med Virol; 2010 May; 82(6):1075-82. PubMed ID: 20419825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular Immune Correlates Preventing Disease Against Respiratory Syncytial Virus by Vaccination with Virus-Like Nanoparticles Carrying Fusion Proteins.
    Lee YT; Ko EJ; Kim KH; Hwang HS; Lee Y; Kwon YM; Kim MC; Lee YN; Jung YJ; Kang SM
    J Biomed Nanotechnol; 2017 Jan; 13(1):84-98. PubMed ID: 29302248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
    Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
    Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein.
    Bembridge GP; Garcia-Beato R; López JA; Melero JA; Taylor G
    J Immunol; 1998 Sep; 161(5):2473-80. PubMed ID: 9725246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engystol reduces onset of experimental respiratory syncytial virus-induced respiratory inflammation in mice by modulating macrophage phagocytic capacity.
    Wronski S; Dannenmaier J; Schild S; Macke O; Müller L; Burmeister Y; Seilheimer B; Müller M
    PLoS One; 2018; 13(4):e0195822. PubMed ID: 29672626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection.
    Rutigliano JA; Graham BS
    J Immunol; 2004 Sep; 173(5):3408-17. PubMed ID: 15322205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Galectin-9 ameliorates respiratory syncytial virus-induced pulmonary immunopathology through regulating the balance between Th17 and regulatory T cells.
    Lu X; McCoy KS; Xu J; Hu W; Chen H; Jiang K; Han F; Chen P; Wang Y
    Virus Res; 2015 Jan; 195():162-71. PubMed ID: 25451068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice.
    Bian C; Liu S; Liu N; Zhang G; Xing L; Song Y; Duan Y; Gu H; Zhou Y; Zhang P; Li Z; Zhang K; Wang Z; Zhang S; Wang X; Yang P
    Antiviral Res; 2014 Apr; 104():110-7. PubMed ID: 24509239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T - helper2 /T - helper1 imbalance in respiratory syncytial virus bronchiolitis in relation to disease severity and outcome.
    Hassan MA; Eldin AM; Ahmed MM
    Egypt J Immunol; 2008; 15(2):153-60. PubMed ID: 20306698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection.
    Harker JA; Lee DC; Yamaguchi Y; Wang B; Bukreyev A; Collins PL; Tregoning JS; Openshaw PJ
    J Virol; 2010 May; 84(10):5294-302. PubMed ID: 20200251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CLEC5A-Mediated Enhancement of the Inflammatory Response in Myeloid Cells Contributes to Influenza Virus Pathogenicity In Vivo.
    Teng O; Chen ST; Hsu TL; Sia SF; Cole S; Valkenburg SA; Hsu TY; Zheng JT; Tu W; Bruzzone R; Peiris JSM; Hsieh SL; Yen HL
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.